Skip to main content
. 2016 Oct 18;9:111. doi: 10.1186/s13045-016-0340-8

Fig. 3.

Fig. 3

Forest plot and pooled HR and 95 % CI for OS (a) and PFS (b): anti-angiogenesis therapy versus non-anti-angiogenesis therapy. The pooled HR for OS and PFS showed that the patients receiving anti-angiogenesis therapy possessed a significant improvement in OS and PFS. HR hazard ratios, OS overall survival, PFS progression-free survival, CI confidence intervals